Weekly exenatide listed for type 2 diabetes
A once-weekly subcutaneous injection of exenatide is being funded on the PBS as part of a $70 million round of new listings.
The glucagon-like peptide-1 (GLP-1) analogue has been available on the PBS as a twice-daily subcutaneous injection (Byetta) since 2010.
On Sunday Federal Health Minister Sussan Ley (pictured) announced the weekly injection (Bydureon) would be available for patients with type 2 diabetes. from 1 September.
The drug will be listed as a PBS authority required (streamlined) benefit for dual combination therapy with metformin or a sulfonylurea, and triple combination therapy with metformin and a sulfonylurea.
Victorian GP Associate Professor Mark Kennedy, chair of the Primary Care Diabetes Society of Australia, says the listing will provide a more convenient treatment option for patients with type 2 diabetes.